More generics on Tarceva over Iressa facing patent expiration

While blockbuster targeted drugs, Roche’s ‘Tarceva’ and AstraZeneca’s ‘Iressa’ will be expired in patent, there are more pharmaceutical companies which acquired approval on Tarceva generics than the one of Iressa even if Iressa made more sales.

Tarceva and Iressa are targeted therapies for non-small cell lung cancer and pancreatic cancer, respectively. The two drugs’ substance patents will end...